New drug to prevent and treat side effects of CAR T-cell therapy
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must be scheduled to receive one of these CAR T-cell therapies for lymphoma or multiple myeloma that has come back or not gone away after at least one prior treatment.
- Your heart, liver, kidneys, and blood counts must be within acceptable ranges for the study.
- You must feel well enough to carry out daily activities (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins on cancer cells (CD20 and CD19) for B-cell cancers like lymphoma and leukemia that have come back or not responded to other treatments. It might help you if your cancer hasn't been controlled by standard options.
This trial tests a rescue medicine given to treat severe immune over-reactions that can happen after CAR T cell therapy, such as cytokine release syndrome and an HLH-like syndrome. It may help calm the immune response if you are already enrolled in a specific CAR T study.
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
Hear when a new Cytokine Release Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.